Bispecific checkpoint inhibitor antibodies
AssigneeXencor, Inc.
InventorsMatthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compositions that include programmed cell death 1 (PD-1) binding domains and antibodies that include such PD-1 binding domains. Also provided are nucleic acid compositions that encode the binding domains and antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.
Claims19
A composition comprising a Programmed Cell Death 1 (PD-1) binding domain, the PD-1 binding domain comprising:
- a) a light chain variable domain comprising a vhCDR1 having SEQ ID NO:
- 37778;
- a vhCDR2 having SEQ ID NO:
- 37779, and a vhCDR3 having SEQ ID NO:
- 37780;
- and
- b) a heavy chain variable domain comprising a vlCDR1 having SEQ ID NO:
- 37782, a vlCDR2 having SEQ ID NO:
- 37783, and a vlCDR3 having SEQ ID NO:
- 37784.
An antibody comprising a PD-1 binding domain, the PD-1 binding domain comprising:
- a) a light chain variable domain comprising a vhCDR1 having SEQ ID NO:
- 37778;
- a vhCDR2 having SEQ ID NO:
- 37779, and a vhCDR3 having SEQ ID NO:
- 37780;
- and
- b) a heavy chain variable domain comprising a vlCDR1 having SEQ ID NO:
- 37782, a vlCDR2 having SEQ ID NO:
- 37783, and a vlCDR3 having SEQ ID NO:
- 37784.
A bispecific antibody comprising:
- a) a first monomer comprising an anti-PD-1 scFv-linker-CH2-CH3, wherein CH2-CH3 is a first IgG Fc domain and the anti-PD1 scFv comprises a first heavy chain variable domain having the amino acid sequence of SEQ ID NO:
- 37781, a first light chain variable domain having the amino acid sequence of SEQ ID NO:
- 37777, and a scFv linker that attaches the first variable heavy chain with the first variable light chain;
- b) a second monomer comprising a VH-CH1-hinge-CH2-CH3, wherein VH is a second heavy chain variable domain and CH2-CH3 is a second IgG Fc domain;
- and
- c) a light chain comprising a second light chain variable domain, wherein the second heavy chain variable domain and second light chain variable domain form an antigen binding domain.
An antibody comprising:
- a) a first monomer comprising a VH1-CH1-linker 1-VL2-scFv linker-VH2-linker 2-CH2-CH3,
- wherein VL2-scFv linker-VH2 is an anti-PD1 scFV, linker 1 and linker 2 are a first linker and second linker, respectively, and CH2-CH3 is a first IgG Fc domain;
- b) a second monomer comprising a VH1-CH1-hinge-CH2-CH3, wherein VH1 is a first variable heavy domain and CH2-CH3 is a second IgG Fc domain;
- c) a common light chain comprising a first variable light domain (VL1);
- and
- wherein the first variable heavy domain on the first monomer and the first variable light domain form a first binding domain, and the first variable heavy domain on the second monomer and the first variable light domain form a second binding domain, and
- wherein the VH2 is a second variable heavy domain having the amino acid sequence of SEQ ID NO:
- 37781 and the VL2 is a second variable light domain having the amino acid sequence of SEQ ID NO:
- 37777.
Dependencies are inferred from the claim text.